efgartigimod
Sponsor Argenx SE · listed as ARGX
READOUT
Phase 2;Phase 3
Confidence: medium
Source: clinicaltrials
Next catalyst
Event typeREADOUT
Expected date2027-03-31
As disclosedMar 2027
Date precisionmonth
Confidencemedium
Trial & sponsor
Trial (NCT)NCT04833894
PhasePHASE2;PHASE3
StatusRECRUITING
Lead sponsorargenx
Listed asARGX
Condition(s)Generalized Myasthenia Gravis
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More ARGX catalysts